Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 8/20 | 0.76 |
| ▸ | HTR2A known ✓ | P28223 | 7/20 | 0.63 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.59 |
| ▸ | HTR1B known ✓ | P28222 | 5/20 | 0.53 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.53 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.53 |
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.50 |
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27570797 | 0.98 | HTR1D (0.78) | HTR1DHTR2AKMT2AMEN1HTR2C | |
| Hydrochloric Acid SCHEMBL7816441 | 0.88 | HTR1D (0.97) | HTR1DHTR2AKMT2AHTR2CPMP22 | |
| SCHEMBL2540516 | 0.86 | HTR1D (1.00) | HTR1DHTR2AKMT2AHTR2CPMP22 | |
| SCHEMBL21008475 | 0.81 | HTR1D (0.53) | HTR1DHTR2AHTR2CHTR1BHTR7 | |
| SCHEMBL23612450 | 0.80 | HTR1D (0.51) | HTR1DHTR2AKMT2AMEN1HTR2C | |
| Hydrochloric Acid SCHEMBL6087688 | 0.80 | HTR2A (0.97) | HTR1DHTR2AKMT2AMEN1HTR2C | |
| Oxalic Acid SCHEMBL2535942 | 0.79 | HTR1D (0.84) | HTR1DHTR2AKMT2AMEN1HTR2C | |
| SCHEMBL1971468 | 0.78 | HTR2A (1.00) | HTR1DHTR2AKMT2AMEN1HTR2C | |
| SCHEMBL20883581 | 0.77 | HTR1D (0.57) | HTR1DHTR2AKMT2AMEN1HTR2C | |
| Hydrochloric Acid SCHEMBL2537521 | 0.76 | HTR2A (0.73) | HTR1DHTR2AKMT2AMEN1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268477-B1 | SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-7348336-B2 | Substituted β-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20060166978-A1 | Substituted beta carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2006-07-27 | — | — | US | disclosed |
| US-7026331-B2 | Substituted beta-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20040110759-A1 | Substituted beta carbolines | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-06-10 | — | — | US | disclosed |
| US-6627637-B2 | I kappa B kinase inhibitors for treating various disorders including arthritis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-30 | — | — | US | disclosed |
| EP-1268477-A1 | SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-20020099068-A1 | Substituted beta carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-07-25 | — | — | US | disclosed |
| EP-1209158-A1 | Substituted beta-carbolines | Aventis Pharma Deutschland GmbH (DE) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001068648-A1 | SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-20 | — | — | WO | disclosed |
| EP-1134221-A1 | Substituted beta-carbolines as lkB kinase inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110759-A1 | Substituted beta carbolines | CSNK1A1, CSNK2A1, CSNK2B | HTR1D 1101/4885HTR2A 1334/4885HTR2C 814/4885 |
| US-20020099068-A1 | Substituted beta carbolines | CSNK1A1, CSNK2A1, CSNK2B | HTR1D 1101/4885HTR2A 1334/4885HTR2C 814/4885 |
| US-20060166978-A1 | Substituted beta carbolines | NFKBIA, RELA, IKBKG | HTR1D 1792/4885HTR2A 1240/4885HTR2C 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.